Gapping up
News:
- TRQ +29% (Rio Tinto (RIO) makes all-cash proposal to acquire full ownership of Turquoise Hill)
- FLGC +5.3% (has signed a distribution agreement with Israel-based DNO Group to distribute the Mind Naturals brand in the Hong Kong region)
- MYGN +5% (receives FDA approval of BRACAnalysis CDx as a companion diagnostic for Lynparza in early breast cancer)
- LUNA +4.2% (acquires LIOS Sensing from NKT A/S's NKT Photonics for €20 million in cash; divested Luna Labs for $21 mln)
- CLNN +3.5% (Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference)
- NVS +1.7% (reports new data reinforcing the benefit of Zolgensma)
- AZN +1.6% (AstraZeneca and Merck's Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer)
- BAC +1.5% (positive Barrons article)
- WFC +1.3% (positive Barrons article)
- C +1.2% (positive Barrons article)
- SCPL +1% (Enginge Capital discloses 8.1% stake; nominates two candidates for election to the Board)
- ECL +1% (announced its intent to repurchase $500 million of its shares in 2022)
- DNA +1% (to acquire Swiss-based strain development and optimization company FGen AG)
Analyst comments:
- DB +8.5% (upgraded to Hold from Sell at Berenberg)
- NOK +4.4% (upgraded to Outperform from Mkt Perform at Raymond James)
- FTV +1.8% (upgraded to Overweight from Equal Weight at Barclays)
- OLN +1.4% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)